Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038666 | 1.00 | KMT2A (0.33) | KMT2AMEN1LMNAL3MBTL1STK17B | |
| SCHEMBL25315958 | 0.86 | L3MBTL1 (0.37) | KMT2AMEN1LMNAL3MBTL1MAPT | |
| SCHEMBL11907830 | 0.80 | L3MBTL1 (0.39) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL5366980 | 0.78 | KMT2A (0.40) | KMT2AMEN1LMNAL3MBTL1ATR | |
| SCHEMBL5375594 | 0.75 | KMT2A (0.34) | KMT2AMEN1LMNAL3MBTL1STK17B | |
| SCHEMBL1661669 | 0.72 | KMT2A (0.47) | KMT2AMEN1LMNAL3MBTL1GAA | |
| SCHEMBL267725 | 0.70 | L3MBTL1 (0.44) | KMT2AMEN1LMNAL3MBTL1MAPT | |
| SCHEMBL30884722 | 0.70 | PARP2 (0.45) | KMT2AMEN1LMNAL3MBTL1MAPT | |
| SCHEMBL1047479 | 0.69 | L3MBTL1 (0.43) | KMT2AMEN1LMNAL3MBTL1MAPT | |
| SCHEMBL3326127 | 0.69 | L3MBTL1 (0.43) | KMT2AMEN1LMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-118488952-A | Substituted quinoline derivatives | 安斯泰来制药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023127814-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2023-07-06 | — | — | WO | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | KMT2A 1551/4885MEN1 3394/4885LMNA 1784/4885 |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | CHRNA4, CHRNA2, CHRNA5 | KMT2A 2084/4885MEN1 3349/4885LMNA 2539/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | KMT2A 1551/4885MEN1 3394/4885LMNA 1784/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | KMT2A 1551/4885MEN1 3394/4885LMNA 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.